Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug

Core Insights - Arrowhead Pharmaceuticals reported that its Phase-3 study for Plozasiran, a treatment for familial chylomicronemia syndrome (FCS), met all primary and key secondary endpoints [1] - The company plans to file a new drug application with the FDA by the end of the year and will also seek approval from other countries [1] - Following the announcement of positive trial results, Arrowhead's shares increased by approximately 2%, although they have lost over 20% of their value since the beginning of the year [1] Company Developments - Plozasiran is aimed at treating FCS, a rare genetic disorder with no currently approved treatments available [1] - Arrowhead's Chief Medical Scientist, Dr. Bruce Given, described Plozasiran as "potentially best-in-class" and supportive of development across various triglyceride disorders [1] Market Reaction - Arrowhead Pharmaceuticals' stock (ARWR) experienced a 2% increase in early trading following the positive trial results [1] - Despite the recent gains, the stock has seen a significant decline of over 20% year-to-date [1]